The University of Southampton
University of Southampton Institutional Repository

Renaissance of cancer therapeutic antibodies

Renaissance of cancer therapeutic antibodies
Renaissance of cancer therapeutic antibodies
In the past five years therapeutic monoclonal antibodies have established themselves as perhaps the most important and rapidly expanding class of therapeutic drugs. More than 25% of pharmacological agents that are currently under development are based on antibodies and the total income generated from them in 2002 exceeded $3 billion, and is predicted to rise to $10–20 billion by 2010. Many experts feel that antibodies directed at cancer targets are likely to dominate the market for the foreseeable future. In this review, we will discuss some of the factors that, after more than 25 years of development, have led to this transformation in the antibody field. Current technology makes the generation of fully-human antibodies a routine procedure. However, selection of appropriate disease targets still represents a challenge. Here we discuss factors that make an effective antibody target and provide an overview of the major issues that are likely to shape this exciting field over the next decade.
antibodies, cancer therapy, apoptosis, specificity
1359-6446
503-510
Glennie, Martin J.
9f6f0eff-4560-48c2-80cd-0ec116110ded
van de Winkel, Jan G.J.
003d19da-52d5-4e0b-84ef-7a1b42b7ae6d
Glennie, Martin J.
9f6f0eff-4560-48c2-80cd-0ec116110ded
van de Winkel, Jan G.J.
003d19da-52d5-4e0b-84ef-7a1b42b7ae6d

Glennie, Martin J. and van de Winkel, Jan G.J. (2003) Renaissance of cancer therapeutic antibodies. Drug Discovery Today, 8 (11), 503-510. (doi:10.1016/S1359-6446(03)02714-4).

Record type: Article

Abstract

In the past five years therapeutic monoclonal antibodies have established themselves as perhaps the most important and rapidly expanding class of therapeutic drugs. More than 25% of pharmacological agents that are currently under development are based on antibodies and the total income generated from them in 2002 exceeded $3 billion, and is predicted to rise to $10–20 billion by 2010. Many experts feel that antibodies directed at cancer targets are likely to dominate the market for the foreseeable future. In this review, we will discuss some of the factors that, after more than 25 years of development, have led to this transformation in the antibody field. Current technology makes the generation of fully-human antibodies a routine procedure. However, selection of appropriate disease targets still represents a challenge. Here we discuss factors that make an effective antibody target and provide an overview of the major issues that are likely to shape this exciting field over the next decade.

This record has no associated files available for download.

More information

Published date: 2003
Keywords: antibodies, cancer therapy, apoptosis, specificity

Identifiers

Local EPrints ID: 26324
URI: http://eprints.soton.ac.uk/id/eprint/26324
ISSN: 1359-6446
PURE UUID: 7215bc57-3d06-4023-84b3-6fa386500fe9

Catalogue record

Date deposited: 19 Apr 2006
Last modified: 15 Mar 2024 07:09

Export record

Altmetrics

Contributors

Author: Jan G.J. van de Winkel

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×